Karyopharm Therapeutics
KPTI
85 hedge funds and large institutions have $285M invested in Karyopharm Therapeutics in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 14 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
25% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $1.91M
15% more capital invested
Capital invested by funds: $248M → $285M (+$37.2M)
4% less funds holding
Funds holding: 89 → 85 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.88M |
| 2 |
JP Morgan Chase
New York
|
+$1.97M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.79M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$687K |
| 5 |
OPPM
Opus Point Partners Management
New York
|
+$653K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.02M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.51M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$6.43M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.04M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.17M |
KPTI Hedge Fund Activity: Q4 2015 in Review
85 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2015, worth a combined $285M — up 15% from $248M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KPTI and 10 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 37 added.
The largest buyer was Millennium Management, adding an estimated $3.88M. The largest seller was Citadel Advisors, cutting an estimated $8.02M.
- 85 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2015, down from 89 in Q3 2015.
- Funds reported $285M of Karyopharm Therapeutics stock for Q4 2015, up 15% quarter-over-quarter.
- 10 funds opened new Karyopharm Therapeutics positions in Q4 2015 and 14 closed out, a net change of -4 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2015 was Millennium Management, an estimated $3.88M added.
- The largest Karyopharm Therapeutics seller in Q4 2015 was Citadel Advisors, an estimated $8.02M sold.
Based on aggregated 13F filings for Q4 2015.